CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
间充质干细胞来源外泌体：肿瘤调控者与靶向肿瘤治疗的载体
英文原题：Mesenchymal stem cell-derived exosome: A tumor regulator and carrier for targeted tumor therapy.
查看英文原题
Mesenchymal stem cell-derived exosome: A tumor regulator and carrier for targeted tumor therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
间充质干细胞（MSCs）是多能基质细胞，具有分化为多种细胞类型的能力。多项研究表明，MSCs 分泌的外泌体（MSCs-Exo）在肿瘤生长、血管生成、侵袭和耐药中发挥重要作用。然而，相互矛盾的结果提示 MSCs-Exo 也可通过特定机制抑制肿瘤，例如调节免疫应答和细胞间信号传导。因此，MSCs-Exo 与肿瘤之间的关系仍存在争议。然而，不可否认的是，外泌体作为天然囊泡，可以成为优良的药物载体，并在靶向肿瘤治疗中展现出应用前景。在此，我们综述了目前关于 MSCs-Exo 参与肿瘤进展及其作为靶向治疗药物递送系统潜力的认识。我们认为 MSCs-Exo 可作为抗肿瘤药物的安全载体。
展开英文摘要原文
Mesenchymal stem cells (MSCs) are multipotent stromal cells that have the ability to differentiate into multiple cell types. Several studies have shown that exosomes secreted by MSCs (MSCs-Exo) play an important role in tumor growth, angiogenesis, invasion, and drug resistance.
However, contradictory results have suggested that MSCs-Exo can also suppress tumors through specific mechanisms, such as regulating immune responses and intercellular signaling. Consequently, the relationship between MSCs-Exo and tumors remains controversial.
However, it is undeniable that exosomes, as natural vesicles, can be excellent drug carriers and show promise for application in targeted tumor therapy.
Here, we review the current knowledge regarding the involvement of MSCs-Exo in tumor progression and their potential as drug delivery systems in targeted therapy.
We argue that MSCs-Exo can be used as safe carriers of antitumor drugs.
论文信息
- 作者
- Zhang F、Guo J、Zhang Z、Qian Y、Wang G、Duan M、Zhao H、Yang Z
- 第一作者单位
- Department of General Surgery, the Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China.China
- 通讯作者单位
- Department of General Surgery, the Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China. Electronic address: 18900912171@163.com.China
- 文献类型
- 非美国政府资助研究 · 综述
- 期刊
- Cancer letters2022 Feb 1
- 原文标识
- PubMed 34800567 · DOI 10.1016/j.canlet.2021.11.015